Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | Chief Medical Officer | August 01, 2025 | October 17, 2025 |
| Enliven Therapeutics, Inc.IMRA · Entity 4024 | Director | June 02, 2022 | June 03, 2022 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Sr. VP & Chief Medical Officer | January 24, 2019 | January 28, 2019 |
| Third Harmonic Bio, Inc.THRD · Entity 76517 | Chief Medical Officer | January 15, 2025 | January 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date August 01, 2025 · Filed October 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 302,260 |
Reported balance
Holding disclosure · report date 2025-08-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 302,260 F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2035-08-08 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-08-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: Twenty Five Percent (25%) of the shares subject to the option vest on August 8, 2026 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof.
F2: Twenty Five Percent (25%) of the shares subject to the option vest on August 8, 2026 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Enliven Therapeutics, Inc.
Report date June 02, 2022 · Filed June 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2032-06-01 | Direct | 8,500 |
Reported balance
After 2022-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-02 · Grant · Acquired 8,500 · Balance 8,500 F1: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant.
SANGAMO THERAPEUTICS, INC
Report date January 24, 2019 · Filed January 28, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,291 |
Reported balance
After 2019-01-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-01-24 · Tax withholding · Disposed 834 · Balance 11,291 F1: Represents shares underlying the portion of the restricted stock unit grant that vested on January 24, 2019 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on January 24, 2019 of $11.10/share, pursuant to the terms of the Issuer's 2013 Stock Incentive Plan. F2: Includes 1,208 shares resulting from the January 24, 2019 vesting of Reporting Person's January 24, 2018 restricted stock unit grant and 4,083 shares subject to such restricted stock unit grant that will vest in two (2) additional equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying the portion of the restricted stock unit grant that vested on January 24, 2019 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on January 24, 2019 of $11.10/share, pursuant to the terms of the Issuer's 2013 Stock Incentive Plan.
F2: Includes 1,208 shares resulting from the January 24, 2019 vesting of Reporting Person's January 24, 2018 restricted stock unit grant and 4,083 shares subject to such restricted stock unit grant that will vest in two (2) additional equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date.
Third Harmonic Bio, Inc.
Report date January 15, 2025 · Filed January 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2035-01-14 | Direct | 132,000 |
Reported balance
After 2025-01-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-15 · Grant · Acquired 132,000 · Balance 132,000 F1: The equity awards of the Reporting Person in this Form 4 were approved on December 17, 2024 by the board of directors as part of the annual refresh equity grant process of the registrant with an effective grant date of January 15, 2025. F2: The option vests over a four-year period: 2.0833% shall vest on February 15, 2025, after which 2.0833% of the total shares vest monthly, subject to contioued service through each vestiog date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 16,500 |
Reported balance
After 2025-01-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-15 · Grant · Acquired 16,500 · Balance 16,500 F3: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F1: The equity awards of the Reporting Person in this Form 4 were approved on December 17, 2024 by the board of directors as part of the annual refresh equity grant process of the registrant with an effective grant date of January 15, 2025. F4: The RSU vests over a four-year period: 1/4 on Febuary 15, 2026, after which 1/4 of the total shares vest annually, subject to contioued service through each vestiog date. |
Filing footnotes · ownership attribution and instrument terms
F1: The equity awards of the Reporting Person in this Form 4 were approved on December 17, 2024 by the board of directors as part of the annual refresh equity grant process of the registrant with an effective grant date of January 15, 2025.
F2: The option vests over a four-year period: 2.0833% shall vest on February 15, 2025, after which 2.0833% of the total shares vest monthly, subject to contioued service through each vestiog date.
F3: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F4: The RSU vests over a four-year period: 1/4 on Febuary 15, 2026, after which 1/4 of the total shares vest annually, subject to contioued service through each vestiog date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Audentes Therapeutics, Inc.
Report date January 15, 2020 · Filed January 15, 2020
Section 16 reporting ended · disclosed 2020-01-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 1
1 source rowRow 1 · 2020-01-15 · Other · Disposed 24,584 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company restricted stock units, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company restricted stock unit was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such Company restricted stock unit immediately prior to such cancellation by (ii) an amount in cash equal to the Offer Price, without any interest. F3: Includes 18,750 shares of Company common stock issuable upon the settlement of restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.08 · Expires 2029-07-15 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-15 · Disposition to issuer · Disposed 90,000 · Balance 0 F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company restricted stock units, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company restricted stock unit was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such Company restricted stock unit immediately prior to such cancellation by (ii) an amount in cash equal to the Offer Price, without any interest.
F3: Includes 18,750 shares of Company common stock issuable upon the settlement of restricted stock units.
F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2025 Filed Jan 17, 2025 18:08 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantRestricted Stock Unit · Derivative | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001723 · form4-01172025_110124.xml · derivative · entry 2 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F1 · kind: The equity awards of the Reporting Person in this Form 4 were approved on December 17, 2024 by the board of directors as part of the annual refresh equity grant process of the registrant with an effective grant date of January 15, 2025. F4 · derivative.exercise_date: The RSU vests over a four-year period: 1/4 on Febuary 15, 2026, after which 1/4 of the total shares vest annually, subject to contioued service through each vestiog date. F4 · derivative.expiration_date: The RSU vests over a four-year period: 1/4 on Febuary 15, 2026, after which 1/4 of the total shares vest annually, subject to contioued service through each vestiog date. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 18:08 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantEmployee Stock Option (right to buy) · Derivative | 132,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001723 · form4-01172025_110124.xml · derivative · entry 1 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,000 Underlying: Common Stock · 132,000 shares Expires 2035-01-14 F1 · kind: The equity awards of the Reporting Person in this Form 4 were approved on December 17, 2024 by the board of directors as part of the annual refresh equity grant process of the registrant with an effective grant date of January 15, 2025. F2 · derivative.exercise_date: The option vests over a four-year period: 2.0833% shall vest on February 15, 2025, after which 2.0833% of the total shares vest monthly, subject to contioued service through each vestiog date. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 17:08 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | Exercise / conversionEmployee Option Grant (right to buy) · Derivative | 2,117 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001415889-24-026626 · form4-11122024_101120.xml · derivative · entry 3 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 368,918 Underlying: Common Stock · 2,117 shares Expires 2032-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the total shares vest on June 6, 2023, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 17:08 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | SaleCommon Stock | 2,117 | $15.00 | $31,755.00 |
DisclosureSEC source: 0001415889-24-026626 · form4-11122024_101120.xml · nonDerivative · entry 2 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated March 27, 2024. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 17:08 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | Exercise / conversionCommon Stock | 2,117 | $4.20 | $8,891.40 |
DisclosureSEC source: 0001415889-24-026626 · form4-11122024_101120.xml · nonDerivative · entry 1 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 16:17 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | Exercise / conversionEmployee Option Grant (right to buy) · Derivative | 2,673 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001415889-24-025750 · form4-10302024_081054.xml · derivative · entry 3 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 371,035 Underlying: Common Stock · 2,673 shares Expires 2032-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the total shares vest on June 6, 2023, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 16:17 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | SaleCommon Stock | 2,673 | $15.00 | $40,095.00 |
DisclosureSEC source: 0001415889-24-025750 · form4-10302024_081054.xml · nonDerivative · entry 2 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated March 27, 2024. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 16:17 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | Exercise / conversionCommon Stock | 2,673 | $4.20 | $11,226.60 |
DisclosureSEC source: 0001415889-24-025750 · form4-10302024_081054.xml · nonDerivative · entry 1 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 17:36 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | Exercise / conversionEmployee Option Grant (right to buy) · Derivative | 4,790 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001415889-24-023788 · form4-09202024_090904.xml · derivative · entry 3 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 373,708 Underlying: Common Stock · 4,790 shares Expires 2032-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the total shares vest on June 6, 2023, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 17:36 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | SaleCommon Stock | 4,790 | $15.00 | $71,850.00 |
DisclosureSEC source: 0001415889-24-023788 · form4-09202024_090904.xml · nonDerivative · entry 2 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated May 15, 2023. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 17:36 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | Exercise / conversionCommon Stock | 4,790 | $4.20 | $20,118.00 |
DisclosureSEC source: 0001415889-24-023788 · form4-09202024_090904.xml · nonDerivative · entry 1 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 16:06 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantEmployee Option Grant (right to buy) · Derivative | 133,000 | $0.00 Strike: $10.89 | $0.00 |
DisclosureSEC source: 0001209191-24-001233 · doc4.xml · derivative · entry 1 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,000 Underlying: Common Stock · 133,000 shares Expires 2034-01-04 F1 · derivative.exercise_date: The option vests over a four-year period: 1/48th on February 5, 2024, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 16:03 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | Exercise / conversionEmployee Option Grant (right to buy) · Derivative | 4,790 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-057712 · doc4.xml · derivative · entry 3 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 378,498 Underlying: Common Stock · 4,790 shares Expires 2032-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the total shares vested on June 6, 2023, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 16:03 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | SaleCommon Stock | 4,790 | $10.03 | $48,062.38 |
DisclosureSEC source: 0001209191-23-057712 · doc4.xml · nonDerivative · entry 2 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated May 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 16:03 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | Exercise / conversionCommon Stock | 4,790 | $4.20 | $20,118.00 |
DisclosureSEC source: 0001209191-23-057712 · doc4.xml · nonDerivative · entry 1 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 17:00 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantEmployee Stock Option (right to buy) · Derivative | 137,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-017233 · doc4.xml · derivative · entry 5 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,000 Underlying: Common Stock · 137,000 shares Expires 2033-03-05 F4 · derivative.exercise_date: The option vests over a four-year period: 1/48th on April 6, 2023, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 17:00 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantEmployee Stock Option (right to buy) · Derivative | 95,000 | Not disclosed Strike: $4.20 | Not disclosed |
DisclosureSEC source: 0001209191-23-017233 · doc4.xml · derivative · entry 4 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2032-10-24 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: The option vests over a four-year period: 1/48th on November 25, 2022, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 17:00 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 95,000 | Not disclosed Strike: $18.40 | Not disclosed |
DisclosureSEC source: 0001209191-23-017233 · doc4.xml · derivative · entry 3 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 95,000 shares Expires 2032-10-24 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: The option vests over a four-year period: 1/48th on November 25, 2022, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 17:00 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantEmployee Stock Option (right to buy) · Derivative | 383,288 | Not disclosed Strike: $4.20 | Not disclosed |
DisclosureSEC source: 0001209191-23-017233 · doc4.xml · derivative · entry 2 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,288 Underlying: Common Stock · 383,288 shares Expires 2032-07-27 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F2 · derivative.exercise_date: 25% of the total shares vest on June 6, 2023, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 17:00 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 383,288 | Not disclosed Strike: $8.61 | Not disclosed |
DisclosureSEC source: 0001209191-23-017233 · doc4.xml · derivative · entry 1 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 383,288 shares Expires 2032-07-27 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F2 · derivative.exercise_date: 25% of the total shares vest on June 6, 2023, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 16:47 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantEmployee Option Grant (right to buy) · Derivative | 95,000 | $0.00 Strike: $18.40 | $0.00 |
DisclosureSEC source: 0001209191-22-054724 · doc4.xml · derivative · entry 1 Conner Edward R. · CIK 0001691265 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2032-10-24 F1 · derivative.exercise_date: The option vests over a 6-month period: 1/6th on October 25, 2022, after which 1/6th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:19 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantStock Options (Right to Buy) · Derivative | 8,500 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001209191-22-034387 · doc4.xml · derivative · entry 1 Conner Edward R. · CIK 0001691265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2032-06-01 F1 · derivative.exercise_date: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 18:44 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantStock Options (Right to Buy) · Derivative | 7,728 | $0.00 Strike: $8.12 | $0.00 |
DisclosureSEC source: 0001209191-21-044076 · doc4.xml · derivative · entry 1 Conner Edward R. · CIK 0001691265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,728 Underlying: Common Stock · 7,728 shares Expires 2031-06-28 F1 · derivative.exercise_date: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant. Read SEC document |
| April 22, 2020 Filed Apr 23, 2020 07:36 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantStock Option (right to buy) · Derivative | 15,457 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-011202 · doc4.xml · derivative · entry 1 Conner Edward R. · CIK 0001691265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,457 Underlying: Common Stock · 15,457 shares Expires 2030-04-21 F1 · derivative.exercise_date: The option vests in three equal installments on April 22, 2021, 2022 and 2023. Read SEC document |
| January 15, 2020 Filed Jan 15, 2020 13:26 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 90,000 | Not disclosed Strike: $36.08 | Not disclosed |
DisclosureSEC source: 0001209191-20-003426 · doc4.xml · derivative · entry 2 Conner Edward R. · CIK 0001691265 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2029-07-15 F4 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 15, 2020 Filed Jan 15, 2020 13:26 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | OtherCommon Stock | 24,584 | $60.00 | $1,475,040.00 |
DisclosureSEC source: 0001209191-20-003426 · doc4.xml · nonDerivative · entry 1 Conner Edward R. · CIK 0001691265 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2 · kind: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company restricted stock units, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company restricted stock unit was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such Company restricted stock unit immediately prior to such cancellation by (ii) an amount in cash equal to the Offer Price, without any interest. F3 · shares: Includes 18,750 shares of Company common stock issuable upon the settlement of restricted stock units. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 18:02 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Tax withholdingCommon Stock | 5,416 | $59.37 | $321,547.92 |
DisclosureSEC source: 0001209191-19-060727 · doc4.xml · nonDerivative · entry 1 Conner Edward R. · CIK 0001691265 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,584 F1 · security: On December 10, 2019, the Compensation Committee of the Issuer's Board of Directors approved the accelerated vesting and settlement of restricted stock units granted on July 15, 2019 in order to mitigate the potential adverse tax consequences of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended. F2 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 16:26 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $36.08 | $0.00 |
DisclosureSEC source: 0001209191-19-042379 · doc4.xml · derivative · entry 2 Conner Edward R. · CIK 0001691265 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-07-15 F2 · derivative.exercise_date: The options will vest as to 25% of the total shares on July 15, 2020, and then 2.0833% of the shares will vest monthly thereafter such that the option is fully vested on July 15, 2023, subject to the Reporting Person's provision of service to the issuer on each vesting date. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 16:26 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-042379 · doc4.xml · nonDerivative · entry 1 Conner Edward R. · CIK 0001691265 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock upon settlement for no consideration. The RSUs will vest as to 25% of the award on September 5, 2020, and then 6.25% of the RSUs will vest quarterly thereafter on each of December 5, March 5, June 5, and September 5 of a given calendar year, such that the RSUs are fully vested on September 5, 2023, subject to the Reporting Person's provision of services to the issuer on each vesting date. Shares of the issuer's Common Stock will be delivered to the Reporting Person following vesting. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 22:46 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 834 | $11.10 | $9,257.40 |
DisclosureSEC source: 0001209191-19-005621 · doc4.xml · nonDerivative · entry 1 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,291 F1 · shares: Represents shares underlying the portion of the restricted stock unit grant that vested on January 24, 2019 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on January 24, 2019 of $11.10/share, pursuant to the terms of the Issuer's 2013 Stock Incentive Plan. F2 · balance_after: Includes 1,208 shares resulting from the January 24, 2019 vesting of Reporting Person's January 24, 2018 restricted stock unit grant and 4,083 shares subject to such restricted stock unit grant that will vest in two (2) additional equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 22:38 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001209191-19-002871 · doc4.xml · derivative · entry 3 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 5,000 shares Expires 2026-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 22:38 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $12.33 | $61,630.50 |
DisclosureSEC source: 0001209191-19-002871 · doc4.xml · nonDerivative · entry 2 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,125 F2 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2017. F3 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $12.17 to $12.44 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 22:38 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $3.20 | $16,000.00 |
DisclosureSEC source: 0001209191-19-002871 · doc4.xml · nonDerivative · entry 1 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,125 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| December 06, 2018 Filed Dec 8, 2018 00:46 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001209191-18-061668 · doc4.xml · derivative · entry 3 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 5,000 shares Expires 2026-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| December 06, 2018 Filed Dec 8, 2018 00:46 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $11.49 | $57,433.00 |
DisclosureSEC source: 0001209191-18-061668 · doc4.xml · nonDerivative · entry 2 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,125 F2 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2017. F3 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $11.31 to $11.78 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 06, 2018 Filed Dec 8, 2018 00:46 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $3.20 | $16,000.00 |
DisclosureSEC source: 0001209191-18-061668 · doc4.xml · nonDerivative · entry 1 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,125 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| November 06, 2018 Filed Nov 7, 2018 22:41 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001209191-18-057677 · doc4.xml · derivative · entry 3 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 5,000 shares Expires 2026-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| November 06, 2018 Filed Nov 7, 2018 22:41 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $13.73 | $68,650.00 |
DisclosureSEC source: 0001209191-18-057677 · doc4.xml · nonDerivative · entry 2 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,125 F2 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2017. F3 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $13.56 to $13.85 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 06, 2018 Filed Nov 7, 2018 22:41 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $3.20 | $16,000.00 |
DisclosureSEC source: 0001209191-18-057677 · doc4.xml · nonDerivative · entry 1 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,125 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Includes 2,000 shares acquired by the Reporting Person on October 31, 2018 under the Issuer's 2010 Employee Stock Purchase Plan, as amended. Read SEC document |
| October 08, 2018 Filed Oct 9, 2018 21:40 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001209191-18-054573 · doc4.xml · derivative · entry 3 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 5,000 shares Expires 2026-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| October 08, 2018 Filed Oct 9, 2018 21:40 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $14.55 | $72,773.50 |
DisclosureSEC source: 0001209191-18-054573 · doc4.xml · nonDerivative · entry 2 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,125 F2 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2017. F3 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $14.39 to $14.79 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 08, 2018 Filed Oct 9, 2018 21:40 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $3.20 | $16,000.00 |
DisclosureSEC source: 0001209191-18-054573 · doc4.xml · nonDerivative · entry 1 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,125 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 20:39 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001209191-18-050085 · doc4.xml · derivative · entry 3 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 5,000 shares Expires 2026-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 20:39 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $14.17 | $70,845.00 |
DisclosureSEC source: 0001209191-18-050085 · doc4.xml · nonDerivative · entry 2 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,125 F2 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2017. F3 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $13.100 to $15.175 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes 6,125 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 20:39 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $3.20 | $16,000.00 |
DisclosureSEC source: 0001209191-18-050085 · doc4.xml · nonDerivative · entry 1 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,125 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| August 06, 2018 Filed Aug 7, 2018 23:28 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001209191-18-045758 · doc4.xml · derivative · entry 3 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 5,000 shares Expires 2026-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| August 06, 2018 Filed Aug 7, 2018 23:28 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $13.45 | $67,250.00 |
DisclosureSEC source: 0001209191-18-045758 · doc4.xml · nonDerivative · entry 2 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,125 F2 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2017. F1 · balance_after: Includes 6,125 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| August 06, 2018 Filed Aug 7, 2018 23:28 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $3.20 | $16,000.00 |
DisclosureSEC source: 0001209191-18-045758 · doc4.xml · nonDerivative · entry 1 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,125 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 22:58 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001209191-18-042044 · doc4.xml · derivative · entry 3 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 5,000 shares Expires 2026-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 22:58 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $15.80 | $78,975.00 |
DisclosureSEC source: 0001209191-18-042044 · doc4.xml · nonDerivative · entry 2 Conner Edward R. · CIK 0001691265 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,125 F2 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2017. F3 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $15.50 to $15.95 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes 6,125 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.